460 related articles for article (PubMed ID: 26040621)
41. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study.
Caravatta L; Padula GD; Picardi V; Macchia G; Deodato F; Massaccesi M; Sofo L; Pacelli F; Rotondi F; Cecere G; Sallustio G; Di Lullo L; Piscopo A; Mignogna S; Bonomo P; Cellini N; Valentini V; Morganti AG
Acta Oncol; 2011 Nov; 50(8):1151-7. PubMed ID: 21851185
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
43. Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study.
Perez K; Safran H; Sikov W; Vrees M; Klipfel A; Shah N; Schechter S; Oldenburg N; Pricolo V; Rosati K; Dipetrillo T
Am J Clin Oncol; 2017 Jun; 40(3):283-287. PubMed ID: 25374145
[TBL] [Abstract][Full Text] [Related]
44. A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
Ueki T; Manabe T; Inoue S; Ienaga J; Yamanaka N; Egami T; Ishikawa M; Konomi H; Ikubo A; Nagayoshi K; Nakamura M; Tanaka M
Anticancer Res; 2016 Feb; 36(2):741-7. PubMed ID: 26851033
[TBL] [Abstract][Full Text] [Related]
45. Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis.
Pasetto LM; Friso ML; Pucciarelli S; Basso U; Toppan P; Rugge M; Sinigaglia G; Nitti D; Sotti G; Monfardini S
Anticancer Res; 2007; 27(2):1079-85. PubMed ID: 17465247
[TBL] [Abstract][Full Text] [Related]
46. Role of neoadjuvant treatment in cT3N0M0 rectal cancer.
Pasetto LM; Friso ML; Pucciarelli S; Basso U; Rugge M; Sinigaglia G; Rossi E; Compostella A; Toppan P; Agostini M; Monfardini S
Anticancer Res; 2008; 28(6B):4129-35. PubMed ID: 19192672
[TBL] [Abstract][Full Text] [Related]
47. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
48. Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial.
Liu L; Cao C; Zhu Y; Li D; Feng H; Luo J; Tang Z; Liu P; Lu K; Ju H; Zhang N
Med Oncol; 2015 Mar; 32(3):70. PubMed ID: 25694046
[TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer.
Huang CM; Huang MY; Ma CJ; Yeh Y-; Tsai HL; Huang CW; Huang CJ; Wang JY
Radiat Oncol; 2017 Mar; 12(1):48. PubMed ID: 28270172
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
[TBL] [Abstract][Full Text] [Related]
51. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
[TBL] [Abstract][Full Text] [Related]
52. [A case of locally advanced rectal cancer responding to FOLFOX].
Kume S; Kubota T; Takahashi M; Hashimoto D; Hirata T; Torigoe Y; Ikeda O
Gan To Kagaku Ryoho; 2009 Apr; 36(4):659-61. PubMed ID: 19381043
[TBL] [Abstract][Full Text] [Related]
53. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
Goldstein D; Mitchell P; Michael M; Beale P; Friedlander M; Zalcberg J; White S; Clarke S
Br J Cancer; 2005 Mar; 92(5):832-7. PubMed ID: 15756253
[TBL] [Abstract][Full Text] [Related]
54. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.
Gérard JP; Chapet O; Nemoz C; Romestaing P; Mornex F; Coquard R; Barbet N; Atlan D; Adeleine P; Freyer G
J Clin Oncol; 2003 Mar; 21(6):1119-24. PubMed ID: 12637479
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
Zhang J; Huang M; Cai Y; Wang L; Xiao J; Lan P; Hu H; Wu X; Ling J; Peng J; Chen D; Kang L; Zhang Y; Ren D; Wang H; Chen S; Lin F; Zheng J; Zhou Z; Wang J; Deng Y
Clin Colorectal Cancer; 2019 Dec; 18(4):238-244. PubMed ID: 31378655
[TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
Park SH; Sung JY; Han SH; Baek JH; Oh JH; Bang SM; Cho EK; Shin DB; Lee JH
Jpn J Clin Oncol; 2005 Sep; 35(9):531-5. PubMed ID: 16027146
[TBL] [Abstract][Full Text] [Related]
57. [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
You KY; Peng HH; Gao YH; Chen L; Zhou GQ; Chang H; Du XJ; Xiao L; Zeng ZF; Wen BX; Liu MZ
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):708-13. PubMed ID: 24332061
[TBL] [Abstract][Full Text] [Related]
58. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
59. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
el Aziz LM
Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
[TBL] [Abstract][Full Text] [Related]
60. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.
Myerson RJ; Tan B; Hunt S; Olsen J; Birnbaum E; Fleshman J; Gao F; Hall L; Kodner I; Lockhart AC; Mutch M; Naughton M; Picus J; Rigden C; Safar B; Sorscher S; Suresh R; Wang-Gillam A; Parikh P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):829-36. PubMed ID: 24606849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
